Sooma is a technology company.
Sooma has raised $5.0M across 1 funding round.
Sooma has raised $5.0M in total across 1 funding round.
Sooma has raised $5.0M in total across 1 funding round.
Sooma's investors include Rockstart, Voima Ventures.
Sooma Medical is a Finnish medtech company founded in 2013 that develops, manufactures, and markets portable, non-invasive transcranial direct current stimulation (tDCS) devices for treating major depressive disorder (MDD), chronic pain conditions like fibromyalgia and neuropathic pain, and other neurological/psychiatric disorders[1][2][3][6]. Its flagship products, such as Sooma tDCS and the 2023-launched Sooma Duo, serve clinics, hospitals, and now direct-to-patient models in select markets, solving the problem of limited access to drug-free, opiate-free therapies amid strained healthcare resources and long waiting times[2][3][7]. With EU MDR approval, ISO 13485 manufacturing, and over 30,000 patients treated across 35+ countries in 250+ clinics, Sooma holds the position of the world's most prescribed tDCS therapy, demonstrating strong growth including FDA Breakthrough Device designation in 2023 and clinical trial approval in 2025[1][2][3][7].
Sooma Oy was established in 2013 in Helsinki, Finland, by co-founders Tuomas Neuvonen (CEO) and Jani Virtanen (Board Member), with key early leaders like Mika Nikander (COO), Maria Kivistö (R&D Manager), and later Peter Hilgert (Chief Commercial Officer)[1][6]. The idea emerged from collaboration with leading psychiatry and clinical neurophysiology experts to address unmet needs in treating depression and chronic pain through science-backed neuromodulation, starting with the first-generation Sooma tDCS device launched in 2014 for MDD[3][6]. Pivotal moments include the 2017 expansion to Sooma Pain Therapy, reaching 20,000+ prescriptions by end-2023, the 2023 Sooma Duo launch with digital platform integration, and regulatory wins like EU MDR certification and U.S. FDA Breakthrough status, enabling global traction from 150+ centers in 35 countries[1][3][7].
Sooma rides the wave of non-invasive neuromodulation and digital therapeutics, addressing global mental health crises—depression affects millions—with drug-free alternatives amid opioid epidemics and pharma resistance[1][4][7]. Timing aligns with post-pandemic demand for accessible care, remote monitoring tech, and regulatory shifts favoring breakthrough devices, amplified by telemedicine growth and healthcare digitization[1][3]. Market tailwinds include rising chronic pain/depression prevalence, clinician shortages, and payer interest in cost-effective outpatient solutions; Sooma influences the ecosystem by normalizing tDCS in 35+ countries, partnering with 250+ clinics, and paving U.S. entry, challenging incumbents and expanding non-pharma options[2][5][7].
Sooma is primed for U.S. market penetration post-2025 FDA trial approval, potentially scaling to match its European dominance with Sooma Duo's direct-to-patient push amid global mental health funding surges[1][7]. Trends like AI-enhanced neuromodulation, personalized brain health platforms, and expanded indications (e.g., beyond depression/pain) will shape its path, with influence growing via IP strength and clinician networks to redefine accessible psychiatry. As the tDCS leader democratizing brain stimulation, Sooma exemplifies medtech's shift toward patient-empowered, non-drug innovation—positioning it to touch millions more lives[2][3].
Sooma has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in March 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2024 | $5.0M Seed | Rockstart, Voima Ventures |